(Q35753546)

10 August 2017

1 reference

title

Poxvirus vaccines for cancer and HIV therapy (English)

1 reference

10 August 2017

1

Shaffiq Essajee

1 reference

10 August 2017

Howard L Kaufman

2

1 reference

PubMed ID

15102606

10 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

Expert Opinion on Biological Therapy

10 August 2017

1 reference

10 August 2017

4

1 reference

10 August 2017

575-588

1 reference

10 August 2017

4

1 reference

Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease

10 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Processing and presentation of antigens by dendritic cells: implications for vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Low levels of HIV-1 infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Impaired interleukin 12 production in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Antibody neutralization and escape by HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Vaccines for the prevention of HIV-1 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

21 January 2018

HIV vaccines 1983-2003.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Development of a DNA-MVA/HIVA vaccine for Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

21 January 2018

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Cancer vaccines and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

p53 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Comparison of the efficacy of early versus late viral proteins in vaccination against SIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Viremia control following antiretroviral treatment and therapeutic immunizationduring primary SIV251 infection of macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

Immunotherapy with Autologous, Human Dendritic Cells Transfected with Carcinoembryonic Antigen mRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

The Feasibility and Safety of Immunotherapy with Dendritic Cells Loaded with CEA mRNA Following Neoadjuvant Chemoradiotherapy and Resection of Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.575

21 January 2018

Identifiers

DOI

10.1517/14712598.4.4.575

1 reference

10 August 2017

1 reference

PubMed ID

15102606